Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

NCT06071767 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

36

Enrollment

NIH

Sponsor class

Conditions

HIV-1-infection

Interventions

BIOLOGICAL: ChAdOx1.tHIVconsv1
BIOLOGICAL: ChAdOx1.HIVconsv62
BIOLOGICAL: MVA.tHIVconsv3
BIOLOGICAL: MVA.tHIVconsv4
DRUG: Vesatolimod (VES)
DRUG: GS-5423
DRUG: GS-2872
BIOLOGICAL: MVA.tHIVconsv4
BIOLOGICAL: Placebo

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]